Florian Klein

Active 1982–2026

174
Papers
20,432
Citations
65
h-index
139
i10-index

Citations

Citations per year for Florian Klein1984: 9 citations1985: 27 citations1986: 14 citations1987: 15 citations1988: 14 citations1989: 2 citations1990: 9 citations1991: 4 citations1993: 4 citations1994: 1 citations1995: 2 citations1996: 1 citations1999: 2 citations2001: 1 citations2002: 5 citations2003: 11 citations2004: 8 citations2005: 11 citations2006: 19 citations2007: 23 citations2008: 21 citations2009: 25 citations2010: 29 citations2011: 20 citations2012: 86 citations2013: 168 citations2014: 243 citations2015: 319 citations2016: 377 citations2017: 304 citations2018: 272 citations2019: 771 citations2020: 972 citations2021: 1,187 citations2022: 1,055 citations2023: 641 citations2024: 824 citations2025: 428 citations2026: 26 citations1992: no citations, so this year is not shown1997–1998: no citations, so these years are not shown2000: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,309 citing papers, 30% of this breakdownGermany: 636 citing papers, 8.3% of this breakdownUnited Kingdom: 499 citing papers, 6.5% of this breakdownChina: 493 citing papers, 6.4% of this breakdownFrance: 313 citing papers, 4.1% of this breakdownCanada: 274 citing papers, 3.6% of this breakdownItaly: 268 citing papers, 3.5% of this breakdownNetherlands: 233 citing papers, 3% of this breakdownAustralia: 216 citing papers, 2.8% of this breakdownSwitzerland: 174 citing papers, 2.3% of this breakdownSpain: 158 citing papers, 2% of this breakdownIndia: 146 citing papers, 1.9% of this breakdown
0%30%Other 25.6%

Fields

  • Medicine49.4%
  • Immunology and Microbiology30.5%
  • Biochemistry, Genetics and Molecular Biology8.6%
  • Computer Science4.9%
  • Neuroscience2.4%
  • Engineering1.7%
  • Other2.5%

Topics

  • HIV Research and Treatment9.1%
  • SARS-CoV-2 and COVID-19 Research7.1%
  • COVID-19 Clinical Research Studies5.1%
  • Immune Cell Function and Interaction4.7%
  • Long-Term Effects of COVID-194.4%
  • Monoclonal and Polyclonal Antibodies Research4.2%
  • Other65.4%

Coauthors

All papers

Open in search
  1. Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Regional Health - Europe 2021 cited by 747

  2. Combination therapy with anti-HIV-1 antibodies maintains viral suppression

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Nico Pfeifer, Gerd Fätkenheuer, Michael S. Seaman, Florian Klein, Marina Caskey, Michel C. Nussenzweig - Nature 2018 cited by 550

  3. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Nature 2015 cited by 783

  4. Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding

    Authors: , , , , , , , , , , , , , , , , , , , , , - Science 2011 cited by 1,192

  5. SARS‐CoV‐2 targets neurons of 3D human brain organoids

    Authors: , , , , , , , , , , , , , , , , , , , , , , - The EMBO Journal 2020 cited by 533

  6. Antibody 10-1074 suppresses viremia in HIV-1-infected individuals

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Pamela J. Björkman, Michael S. Seaman, Beatrice H. Hahn, Gerd Fätkenheuer, Sarah J. Schlesinger, Michel C. Nussenzweig, Florian Klein - Nature Medicine 2017 cited by 510

  7. In-depth virological and immunological characterization of HIV-1 cure after CCR5Δ32/Δ32 allogeneic hematopoietic stem cell transplantation

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Monique Nijhuis, Asier Sáez‐Cirión, Julian Schulze zur Wiesch, Annemarie M. J. Wensing, Javier Martínez‐Picado, Guido Kobbe - Nature Medicine 2023 cited by 154

  8. CD86+ Antigen-Presenting B Cells Are Increased in Cancer, Localize in Tertiary Lymphoid Structures, and Induce Specific T-cell Responses

    Authors: , , , , , , , , , , , , , , , , - Cancer Immunology Research 2021 cited by 95

  9. Early antibody therapy can induce long-lasting immunity to SHIV

    Authors: , , , , , , , , , , , , , , , , , , - Nature 2017 cited by 317

  10. HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Beatrice H. Hahn, Michel C. Nussenzweig, Marina Caskey - Nature 2016 cited by 482

  11. Augmented/Mixed Reality Audio for Hearables: Sensing, control, and rendering

    Authors: , , , , , , , , - IEEE Signal Processing Magazine, IEEE Signal Process. Mag. 2022 cited by 52

  12. HIV-1 Integration Landscape during Latent and Active Infection

    Authors: , , , , , , , , , , , , , , , , - Cell 2015 cited by 473

  13. Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity

    Authors: , , , , , , , , , , , , , - Nature Medicine 2020 cited by 164

  14. Antibody-mediated neutralization of SARS-CoV-2

    Authors: , , , , , - Immunity 2022 cited by 152

  15. Perceptual Matching of Room Acoustics for Auditory Augmented Reality in Small Rooms - Literature Review and Theoretical Framework

    Authors: , , - Trends in Hearing 2022 cited by 53

  16. Somatic Mutations of the Immunoglobulin Framework Are Generally Required for Broad and Potent HIV-1 Neutralization

    Authors: , , , , , , , , , , , , , , , - Cell 2013 cited by 570

  17. Broadly Neutralizing Anti-HIV-1 Antibodies Require Fc Effector Functions for In Vivo Activity

    Authors: , , , , , - Cell 2014 cited by 513

  18. HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1

    Authors: , , , , , , , , , , , , , , , , , , , - Science 2016 cited by 316

  19. Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Marina Caskey, Florian Klein, Michel C. Nussenzweig - Nature Medicine 2018 cited by 262

  20. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Nature 2013 cited by 643

  21. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Cell 2020 cited by 398

  22. Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Microbe 2022 cited by 82

  23. Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic

    Authors: , , - Nature Medicine 2019 cited by 240

  24. Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Cell 2020 cited by 159